03:25 AM EST, 11/11/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We trim our 12-month target price by $6 to $100, representing 12.0x our 2026 EPS estimate, which is a discount to ZBH's three-year average forward P/E of 14.6x. We trim our 2025 EPS estimate by $0.04 to $8.16 and increase our 2026 EPS forecast by $0.03 to $8.35. While ZBH delivered strong Q3 U.S. growth of 5.6% - the best performance in over two years - supported by the adoption of innovative products like Persona OsseoTi and the Oxford Partial Cementless Knee, late-quarter challenges in Eastern Europe, Latin America, and non-core restorative therapies businesses resulted in a 120-basis-point headwind and narrowed full-year organic growth guidance to 3.5%-4.0%. Management's acknowledgment of execution issues in certain international markets and non-core segments, coupled with the need for more measured external commentary, reflects ongoing commercial execution challenges that must be addressed. Our Hold rating reflects a balanced risk-reward, with solid innovation momentum offset by execution uncertainties.